Search BRTX
BioRestorative Therapies, Inc.
NasdaqCM · CIK 1505497
Last close2.14
Daily change-0.13 (-5.73%)
10 Years gain-99.98%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BRTX · STANDARD
SIC 8090 · Services-Misc Health & Allied Services, NEC · Fiscal year end 1231
Fundamental
47.2Momentum
0.0Acceleration
0.0Confidence
70.0Annual Revenue15
Quarterly Revenue51
Annual CFO13
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 1104.5537 percentage points.
Heavy share dilution · HIGHDiluted share count increased 118.2817%.
Key Metrics
Revenue Growth TTM-6.47%OK
Revenue CAGR 3Y44.27%OK
Gross Margin91.85%OK
Operating Margin-4,186.3%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y678.91%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y118.28%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $359,700.00 | $335,856.00 | -$15.65M | -$10.79M | -$10.91M | 93.37% | -4,350.05% | -3,031.7% | n/a | 8.99M |
| 2025 FY Dec 31, 2024 | $401,000.00 | $372,928.00 | -$11.56M | -$8.23M | -$8.34M | 93% | -2,881.59% | -2,078.94% | n/a | 7.76M |
| 2024 FY Dec 31, 2023 | $145,800.00 | $145,800.00 | -$15.22M | -$6.43M | -$6.60M | 100% | -10,439.49% | -4,527.61% | n/a | 4.22M |
| 2023 FY Dec 31, 2022 | $119,800.00 | $119,800.00 | -$18.97M | -$5.91M | -$6.18M | 100% | -15,838.08% | -5,157.2% | n/a | 3.62M |
| 2022 FY Dec 31, 2021 | $46,000.00 | $46,000.00 | -$26.31M | -$3.33M | -$3.36M | 100% | -57,191.03% | -7,305.58% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $363,270.00 | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-023126, 0001641172-25-023211 |
| Revenue Growth TTM | -6.47% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-023126, 0001641172-25-023211 |
| Revenue CAGR 3Y | 44.27% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-012925 |
| Revenue CAGR 5Y | 36.11% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-012925 |
| Gross Profit CAGR 3Y | 41% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-012925 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-023126, 0001641172-25-023211 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 91.85% | Gross Profit / Revenue | OK | 0001493152-26-023126, 0001641172-25-023211 |
| Operating Margin | -4,186.3% | Operating Income / Revenue | OK | 0001493152-26-023126, 0001641172-25-023211 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-023126 |
| Current Ratio | 2.35x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.02 | Revenue / Diluted Shares | OK | 0001493152-26-023126, 0001641172-25-023211 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001493152-26-012925 |